International Speakers

Dr. Marina Chiara Garassino  As a medical oncologist, Dr Garassino has researched precision medicine and immuno-oncology. Dr Garassino main research interests include; the development of new drugs, therapeutically strategies and biomarkers. Dr Garassino has contributed to over 120 peer-reviewed publications, including credits as first or last author in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology and has delivered many presentations at international conferences including AACR, ASCO, ECCO, ESMO, WCLC.

Dr. Federico Cappuzzo has been the Director of Medical Oncology at AUSL della Romagna-Ravenna since April 2016 and has been the Director on Hematology and Oncology Department since January 2017. He has authored more than 200 papers in peer-review journals, mainly in translational research in lung cancer.

Professor Nir Peled MD, PhD, FCCP is the Associate Professor at the Faculty of Medicine, Ben-Gurion University, Beer Sheva, Israel. He is a pulmonologist and medical oncologist. Prof. Peled is the Director of the Cancer Center at Soroka Medical Center. In addition, Prof. Peled is the head of the Thoracic Oncology Assembly of the European Respiratory Society (ERS) and the Chair of the Early Detection & Prevention Committee of the IASLC.  Prof. Peled focuses on the wide clinical and translational perspectives of lung cancer and studies specifically the biomarkers of lung cancer, personalized based medicine in lung cancer and immuno-oncology.

Find out more long-arrow-right

Wednesday 19 February

Time Session
9:00am - 4:00pm Faculty of Radiation Oncology Lung Interest Cooperative (FROLIC) Workshop (Dr. Louis Lao, A/Prof Gerry Hanna)
9:00am - 4:00pm Australia and New Zealand Lung Cancer Nurses Forum (ANZ-LCNF) Nursing and Allied Health Workshop (Proudly Sponsored By Roche)

Session 1: Quality In Diagnostics & Care

• The Impact Of The Specialist Lung Cancer Nurse Model On The Health & Wellbeing Outcomes Of Patients And Families (Prof Angela Tod – UK)

• Evaluation Of The Lung Cancer Optimal Care Pathways

• 2020: A Year In Review Of Lung Cancer

• Tecentriq And Avastin Combination Therapy (Roche)

Session 2: Hope & Equity

• The Lived Experience (Consumer Advocate Presentation)

• Telehealth To Improve Access And Equity To Cancer Survivorship Care (Lung Cancer Nurse Specialist, Vanessa Brunelli)

• Representation Of Minorities In Clinical Trials

• Cerebral Metastases And Radiotherapeutic Advances (Dr. Nikki Plumridge)

• Respiratory Health And Mesothelioma

Session 3: Living With Thoracic Cancer And Beyond

• Symptom Management – Challenges Faced With New Immune-Oncology Therapies (Lung Cancer Nurse Specialist, Caitlin Broderick)

10:00am - 5:00pm Australasian Lung Cancer Trials Group (ALTG) Clinical Development Workshop and open SAC meeting
10:00am - 3:00pm Lung Cancer Community Forum

• Treatment

• Innovation

• Mental Health & Wellness

Thursday 20 February

Time Session
7:00am - 8:00am Australasian Lung Cancer Trials Group MAC Meeting

(ALTG members only)

8:00am - 9:00am Opening Ceremony
9:00am - 10:00am Keynote Presentation
10:00am - 10:30am Morning Tea and Poster Presentations
10:30am - 12:30pm Palliative Care Symposium

• Introduction; cancer patients' perspectives of palliative care (Dr Jackie Yoong)

• Research on the patient perspective (A/Prof Jane Phillips)

• Inpatient Palliative Care Services

• Community Palliative Care Services (Dr Eswaran Waran)

• Early Palliative Care (Prof David Carrow)

• Palliative Care Research Update (Prof Jane Phillips)

10:30am - 12:30pm Plenary - Quality in Diagnostics and Care: ‘Leaps & Bounds’ in Lung Cancer in 2020

Chairs: A/Prof Tom John

• Science & Pathology (A/Prof Marie-Liesse Labat)

• Diagnostics (Prof. Stephen Fox)

• Medical Oncology (Targeted Therapy)

• Radiation Oncology (A/Prof Gerry Hanna)

• Surgery (A/Prof Gavin Wright)

• Allied Health (Dr Lara Edbrooke)

• Nursing (Lung Cancer Nurse Specialist, Mary Duffy)

• Speaker Panel

10:30am - 12:00pm Pfizer Symposium - Lung Pathology In the Era of Targeted Therapies: ROS1 Testing in Patients with Advanced Non-Small Cell Lung Cancer (A/Prof Nick Pavlakis and A/Prof Wendy Cooper)
10:30am - 12:30pm Poster Viewing
12:30pm - 1:30pm Lunch and Poster Presentations
12:30pm - 2:00pm Roche Symposium - Non-Squamous NSCLC: Selecting The Right Treatment Regimen for Each Patient (Dr. Federico Cappuzzo – Italy)
1:30pm - 3:00pm Basic Science Symposium: Novel insights into the biology of thoracic cancers

Chairs: A/Prof Marie-Liesse Asselin-Labat and Dr. Kate Sutherland

• Dichotomising high dimensional data: exploring immune checkpoint blockade response with bulk and single cell RNA sequencing (Dr. Melvin Chin)

• Interrogating the immune microenvironment in primary lung cancer and metastases (Dr. Clare Weeden)

• Targeting epigenetic dysregulation in SWI/SNF-deficient lung adenocarcinoma (Dr. Jason Cain)

• Exploiting cell cycle-mediators to enhance chemotherapy response in non-small cell lung cancer (Dr. Mark Adams)

• Identifying therapeutic approaches to treat KEAP1-mutant lung adenocarcinoma (Dr. Sarah Best)

• Mechanisms of immune evasion in small cell lung cancer (Dr. Marian Burr)

1:30pm - 3:30pm New Investigator Oral Abstract Presentations
1:30pm - 3:30pm Plenary - Hope & Equity: Reinventing Clinical Trials

• Real world research participation: Setting the Stage (Consumer Advocate presentation)

• Representation of minorities in oncology clinical trials

• Debate (featuring surprise debaters!)

  o Argument: Lung cancer patients should have access to clinical trials. Relax the eligibility criteria!

  o Rebuttal: Strict criteria are crucial in clinical trials to ensure scientific purity. Do not relax the eligibility criteria!

• PROMs, PREMs and Quality: Partnering with Patients to Develop Meaningful Measures (A/Prof Rob Stirling)

• Beyond 3rd Generation: Innovation in Clinical Trials (Prof Ben Solomon)

• Speaker panel discussion: Clinical trials: “I want the future….”

1:30pm - 3:30pm Living with Thoracic Cancer and Beyond: Exercise in Lung Cancer

Chairs: Dr Lara Edbrooke and Dr Ashanya Malalasekera

• Update: Exercise Oncology Guidelines and Position Statements (Prof Rob Newton)

• Mechanisms behind the effects of exercise in lung cancer

• Prehab & Prehab Guidelines in Oncology (Prof Linda Denehy)

• Advances in evidence for exercise following surgery and for those with inoperable disease (Dr Vinicius Calvalheri)

• Models of exercise prescription and community engagement in survivorship the real-world experience (Jane Turner)

1:30pm - 3:30pm Poster Viewing
4:00pm - 6:00pm Australasian Lung Cancer Trials Group (ALTG) Clinical Trial Concepts

(all delegates welcome)

4:00pm - 5:00pm New Investigator Oral Abstracts
4:00pm - 5.30pm Plenary - Living with Thoracic Cancer and Beyond: Holistic Long-term Care

• The lived experience of long-term survivors (Consumer Advocate presentation)

• Patient experience research of unmet need: the PEEK Study (Dr Catherine Holliday)

• Models of survivorship care and long-term surveillance: What works? (Dr. Joel Rhee)

• What we can learn from Palliative Care colleagues: a positive blend of Palliative Care and Survivorship (Dr. Jackie Yoong)

• Voluntary Assisted Dying: what you and your patients want to know (Jacqueline Lesage, Consumer Advocate)

Followed by speaker panel discussion

6:00pm - 7:30pm Merck Sharp & Dohme Symposium - Redefining Survival Expectations For Lung Cancer Patients (Prof. Nir Peled – Israel)
7:00pm - 07:30pm Lung Foundation Australia Welcome Cocktail Reception
7:30pm - 11:00pm Lung Foundation Australia Dinner (including Lung Cancer Research Awards)

Friday 21 February

Time Session
7:00am - 9:00am Australasian Lung Cancer Trials Group (ALTG) Strategic Planning Meeting

(ALTG members only)

7:30 am - 9:00 am Bristol Myers Squibb Symposium - Real-World Data in NSCLC (Prof. Michael Boyer - Sydney)
7:30am - 9:00am Cancer Australia – Resource Launch: Investigating Symptoms of Lung Cancer: A Guide for Health Professionals (Prof Danielle Mazza)
9:00am - 10:00am Keynote presentation: Working together: The Power of a Multi-Disciplinary Approach in Lung Cancer Treatment & Care (Prof. Angela Tod - UK)
10:00am - 10:30am Morning Tea, Poster Viewing and Presentations
10:30am - 12:30pm Oral Abstract Presentations

• Rapid Fire Group Presentations

• Standard Oral Presentations

10:30am - 12:30pm Oral Abstract Presentations

• Standard Oral Presentations

10:30am - 12:30pm Symposium: Borderline Inoperable Disease (tracks: radiology / radiation oncology / surgery)

• Optimal surgical management of stage 1 disease

• What role for non-surgical treatment in stage 1 disease? (A/Prof Gerry Hanna)

Followed by speaker panel discussion

• Surgery in stage 3 disease: is there a role?

• Should all stage 3 disease be treated with radiation therapy treatments? (A/Prof Gerry Hanna)

Followed by speaker panel discussion

10:30am - 12:30pm Poster Viewing
10.30am - 12:30pm Plenary - Quality in Diagnostics & Care: Lung Cancer Screening in Australia

• Setting the scene: The Cancer Australia Enquiry (Cancer Australia)

• Screening and smoking cessation • Screening and comorbidities

• Considerations in computer-aided detection, radiomics and artificial intelligence (AI)

• Maximising uptake: the hard to reach and underserved

• Looking to international efforts to drive local implementation

Followed by speaker panel discussion

12:30pm - 2:00pm AstraZeneca Symposium - Putting evidence into practice in locally advanced and metastatic NSCLC (Dr. Marina Garassino - Milan)
12:30pm - 1:30pm Lunch and Poster Presentations
1:30pm - 3:00pm Oral Abstract Presentations

• Standard Oral Presentations

1:30pm - 3:00pm Oral Abstract Presentations

• Standard Oral Presentations

1:30pm - 3:30pm Plenary - Hope & Equity: Toward 2030 – Achieving Hope and Equity Over The Next Decade

• Engaging The Patient Voice (Dr. Lisa Briggs, Consumer Advocate)

• Nurse Led Models (Prof. Angela Tod – UK) • Equity: Do We Have It?

• Using Health Systems Data to Drive And Monitor Change

• Learnings From The Victorian Lung Cancer Registry (A/Prof Rob Stirling)

Followed by speaker discussion panel: Blue skies; where do we want to be in 2030 and how will we get there?

1:30pm - 3:30pm Mesothelioma and Rare Thoracic Cancers Symposium

• Epidemiology (Prof Fraser Brims)

• Genomics and Mesothelioma

• Surgical Approaches To Mesothelioma (A/ Prof Gavin Wright)

• Advances In Systemic Therapy (Prof Ken O’Byrne)

• Novel Targets For Treatment (Prof Anna Nowak)

• What Role For Radiation Therapy In Mesothelioma (A/Prof Gerry Hanna)

Followed by speaker panel discussion

4:00pm - 5:00pm Poster Removal
3:30pm - 4:30pm Abstract & Poster Awards

Closing Ceremony

4:30pm- 4:45pm Afternoon Tea

Program at a Glance

The ALCC program is aligned to the recommendations of Making a Lung Cancer a Fair Fight: A BluePrint for Reform report and is presented in three core streams:

  • Quality in Diagnostics and Care
  • Living with Thoracic Cancer and Beyond
  • Hope and Equity

Registration is required for sponsor symposiums and workshops (FROLIC; ANZ-LCNF; ALTG) and can be added to your single-day or full conference registration.

Consumer Advocates Lounges

A dedicated networking area will be exclusively accessible for lung cancer consumer advocates attending ALCC 2020. Located within the main conference area, you can rest, recover and catch up with friends. Light refreshments will be served throughout the day and a variety of seating and charging stations will be available.


Download long-arrow-right

In collaboration with

Proudly sponsored by